All in: Boehringer In­gel­heim more than dou­bles its ven­ture fund to €250M

In a move that re­flects the in­creas­ing­ly ac­tive role cor­po­rate VCs are play­ing in biotech, Ger­man phar­ma gi­ant Boehringer In­gel­heim is fun­nel­ing an ad­di­tion­al …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER